Article Sidebar
Published:
Sep 16, 2014DOI:
10.4314/tjpr.v13i7.5Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
In vitro Evaluation of PEGylated-Mucin Matrix as Carrier for Oral Delivery of Metformin Hydrochloride
Abstract
Purpose: To formulate metformin hydrochloride-loaded PEGylated-mucin microparticles and evaluate their in vitro properties.
Method: Three different formulations of metformin hydrochloride (MTH) (PEG-M1, PEG-M2 and PEGM3) were prepared using PEGylation method. PEG-8000 and snail mucin, in a ratio of 1:3, were PEGylated together using solvent interaction principle. Loading of MTH into the matrix was by diffusion method and the microparticles characterized for particle size, zeta potential, polydispersity index, stability and in vitro release in phosphate buffer (pH 7.4).
Results: Maximum yield and encapsulation were 97 and 87 % respectively. Zeta potential was -37.7, - 42.3 and -46.2 mV for PEG-M1, PEG-M2 and PEG-M3 with a corresponding polydispersity index (PDI) of 0.320, 0.374 and 0.398, respectively. Particles size was 85, 115, and 145 μm for PEG-M1, PEG-M2 and PEG-M3, respectively, and they showed a unimodal distribution. Drug release was biphasic and exhibited controlled release pattern with maximum release of 92 % in 18 h compared to 81 % in 6 h for the conventional formulation.
Conclusion: Extended release metformin hydrochloride formulations were successfully developed using PEGylated mucin matrices.
Keywords: Drug delivery, Extended release, Polyethylene glycol, Mucin PEGylation, Encapsulation, Zeta potential, Polydispersity index
